Dr. Taksey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
810 Bestgate Rd
Suite 400
Annapolis, MD 21401Phone+1 410-897-6200Fax+1 410-266-7636- Is this information wrong?
Summary
- Dr. Jason Taksey is an oncologist in Annapolis, MD and is affiliated with University of Maryland Baltimore Washington Medical Center. He received his medical degree from Penn State College of Medicine and has been in practice 16 years. He specializes in genitourinary oncology and is experienced in prostate cancer, kidney cancer, urologic oncology, bladder cancer, and testicular cancer.
Education & Training
Temple University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007- Temple University HospitalResidency, Internal Medicine, 2003 - 2004
Medical University of South CarolinaResidency, Internal Medicine, 2001 - 2003
Pennsylvania State University College of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2006 - 2025
PA State Medical License 2003 - 2008
SC State Medical License 2002 - 2003- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Publications & Presentations
PubMed
- Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) wi...Keizman D, Ish-Shalom M, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, Boursi B, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA> ;J. Clin. Oncol.. 2012-02-10
- Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib.Keizman D, Ish-Shalom M, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, Boursi B, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA> ;J. Clin. Oncol.. 2012-02-10
- 9 citationsFertility after chemotherapy for testicular cancer.J Taksey, Nabil K. Bissada, Uzair B. Chaudhary> ;Archives of Andrology. 2003 Sep 1
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
